News/Publications
Systematic Literature Review of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia - Need for a Disease-Specific Tool.
Bristogiannis, Sotirios, Jahanzaib Khwaja, Yadanar Lwin, Encarl Uppal, Shirley D'Sa, and Charalampia Kyriakou.
eJHaem n/a, no. n/a
Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab Is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia
Buske, C., A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, J. V. Matous, C. S. Tam, L. T. Heffner, M. Varettoni, M. L. Palomba, C. Shustik, E. Kastritis, S. P. Treon, J. Ping, B. Hauns, I. Arango-Hisijara, and M. A. Dimopoulos.
Future Oncol (Feb 23 2023).
Members
Members
- BNLI (R. Owen/UK)
- Czech Myeloma Group (R. Hajek/Czech Republic)
- FIL Italian Intergroup (A. Tedeschi/Italy)
- FCGCLLWM Group (P. Morel, X. Leleu, V.LeBlond/France)
- GLA/OSHO (C. Buske, M. Dreyling, M. Herold/Germany)
- Greek Myeloma Study Group (M. Dimopoulos, E. Kastritis/Greece)
- HOVON (M.-J. Kersten/Netherlands)
- Nordic Lymphoma Group (E. Kimby/Sweden)
- Portuguese Lymphoma Study Group (M. Gomes da Silva/Portugal)
- Spanish Study Group (R. Garcia Sanz/Spain)
In association with the "Australasian Leukaemia & Lymphoma Group" (ALLG).
Login
Here you will find the communication platform of "European Consortium for Waldenstrom's Macroglobulinemia". Log in here with your user name and password. If you do not have access, you can get it by email via our contact form.